HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'
HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'
HC Wainwright 对 TherapeuticSMD 的评级和目标股价正在审查中，原因是 “路径不明确”
- The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ:TXMD) was terminated, with EW Partners not acquiring the majority of shares to complete the tender offer successfully.
- HC Wainwright said it is unclear what non-tendering shareholders hoped to accomplish.
- The tender offer documents indicated that EW at times considered bids as high as $18/share, so perhaps investors not tendering hoped that EW would increase their bid.
- After the unsuccessful tender and termination of the merger agreement, TherapeuticsMD reached an agreement with its creditors, in which the maturity date of the financing agreement was amended to July 24, 2022.
- TXMD noted that it is considering filing for Chapter 11 bankruptcy or could also try to restart the sale process,
- HC Wainwright's price target and rating are under review as the company seeks to identify a path forward.
- TXMD is not currently generating a profit, and its liquidity could negatively affect the company's ability to sell Annovera, its largest commercial product.
- Price Action: TXMD shares are up 3.13% at $5.45 during the market session on the last check Friday.
- EW Partners与TherapeuticSMD Inc（纳斯达克股票代码：TXMD）之间的合并协议已终止，EW Partners没有收购大部分股份来成功完成要约。
- HC Wainwright表示，目前尚不清楚非招标股东希望实现什么目标。
- 要约文件显示，EW有时认为出价高达每股18美元，因此可能没有投标的投资者希望EW提高出价。
- 在招标失败和合并协议终止后，TherapeuticSMD与其债权人达成协议，将融资协议的到期日修改为2022年7月24日。
- TXMD指出，它正在考虑申请第11章破产，或者也可能尝试重启出售程序，
- HC Wainwright的目标股价和评级正在审查中，因为该公司正在寻求寻找前进的道路。
- TXMD目前没有盈利，其流动性可能会对该公司出售其最大的商业产品Annovera的能力产生负面影响。
- 价格走势：在周五最后一次支票的市场交易中，TXMD股价上涨3.13％，至5.45美元。